Rationale and Design of a Phase II Trial of Combined Serplulimab and Chemotherapy in Patients with Histologically Transformed SCLC: a Prospective, Single-Arm and Multicenter Study

Transformed small cell lung cancer (T-SCLC) is a highly aggressive clinical disease with a notably poor prognosis. It most often arises from epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) following treatment. To date, no standard treatment has been established for T-SCLC. Platinum-etoposide was the most commonly used regimen, but progression-free survival remains unsatisfactory. Therefore, there is an urgent unmet need to develop novel and effective strategies for this population.

Source: Clinical Oncology - November 10, 2023 Category: Radiology Authors: Jie Huang, Xiu-Hao Zhang, Yongguang Cai, Dongyong Yang, Jian Shi, Puyuan Xing, Tao Xu, Longqiu Wu, Wenmei Su, Ruilian Xu, Ting Wei, Hua-Jun Chen, Jin-Ji Yang Tags: Original Article Source Type: research